bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Brokerages

bioMerieux (OTCMKTS:BMXMF) has earned an average recommendation of “Reduce” from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company.

BMXMF has been the topic of several analyst reports. Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Zacks Research upgraded bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Finally, UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st.

bioMerieux Stock Performance

Shares of OTCMKTS:BMXMF opened at $78.99 on Friday. The company has a 50 day moving average of $81.38 and a two-hundred day moving average of $99.76. bioMerieux has a 52-week low of $77.00 and a 52-week high of $152.00. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.